Enteric Neuroimmune Axis Dysfunction in Functional Gut Disorders

Abstract

The enteric neuroimmune axis is increasingly recognized as a critical interface mediating gut-brain signaling, immune modulation, and gastrointestinal homeostasis. Dysfunction of this axis underpins the pathogenesis of various functional gut disorders, notably irritable bowel syndrome (IBS) and functional dyspepsia. This review synthesizes current evidence on the epidemiology, mechanistic underpinnings, risk factors, clinical manifestations, diagnostic strategies, and management of neuroimmune axis dysfunction in functional gut disorders. Emphasis is placed on recent advances in neuroimmune pharmacology, microbiome-immune interactions, and guideline-based clinical approaches, providing a comprehensive, clinically relevant resource for healthcare professionals.

Introduction

Functional gut disorders, notably IBS and functional dyspepsia, are characterized by chronic gastrointestinal symptoms without identifiable structural or biochemical abnormalities. Increasingly, research implicates the enteric neuroimmune axis-a complex network involving enteric neurons, glia, immune cells, and gut microbiota-in the pathophysiology of these conditions. Understanding the bidirectional communication within this axis is essential for unraveling disease mechanisms and informing innovative therapeutic strategies. This review examines the state-of-the-art knowledge regarding enteric neuroimmune dysfunction, with clinical and translational implications for practice.

Epidemiology / Disease Burden

Functional gut disorders affect up to 16% of the global population, with IBS alone impacting approximately 11%. These conditions represent a substantial disease burden, accounting for significant healthcare utilization, reduced quality of life, and lost productivity. Epidemiological studies reveal higher prevalence among females and younger adults, though all ages and ethnic groups can be affected. Notably, the heterogeneity in symptom presentation and severity complicates epidemiological assessments. Recent data suggest rising incidence, possibly linked to changing dietary habits, psychosocial stressors, and environmental exposures that may influence neuroimmune function.

Pathophysiology

The pathogenesis of functional gut disorders is multifactorial, with the enteric neuroimmune axis playing a central role. Under physiological conditions, enteric neurons, immune cells (notably mast cells and macrophages), and the gut microbiota communicate to regulate motility, secretion, and barrier integrity. Dysregulation occurs via heightened immune activation, increased pro-inflammatory cytokine release, altered neurotransmission (e.g., serotonin dysregulation), and impaired mucosal barrier function. Microbiota-derived metabolites modulate both neural and immune pathways, with dysbiosis promoting aberrant signaling. Neuroimmune dysfunction results in visceral hypersensitivity, motility disturbances, and low-grade mucosal inflammation-the pathophysiological hallmarks of IBS and related disorders.

Risk Factors

Multiple risk factors predispose individuals to neuroimmune axis dysfunction and subsequent functional gut disorders. Genetic susceptibility influences immune reactivity and neurotransmitter signaling. Early life stress, psychosocial comorbidities (anxiety, depression), infections (post-infectious IBS), dietary factors (FODMAPs, food antigens), antibiotic exposure, and alterations in the gut microbiome are well-established contributors. Environmental toxins and chronic stress potentiate neuroimmune dysregulation by activating the hypothalamic-pituitary-adrenal (HPA) axis and altering mucosal immune responses.

Clinical Features

Patients typically present with chronic or recurrent abdominal pain, bloating, altered bowel habits (diarrhea, constipation, or mixed patterns), and extraintestinal symptoms such as fatigue or anxiety. Symptom patterns often fluctuate and are exacerbated by stress or certain foods. Notably, symptom severity does not always correlate with the degree of mucosal inflammation, underscoring the complex neuroimmune interplay. Alarm features (weight loss, rectal bleeding, nocturnal symptoms) warrant further evaluation to exclude organic pathology.

Diagnosis

Diagnosis is clinical, based on Rome IV criteria for functional gut disorders, which emphasize symptom duration and pattern. A detailed history and physical examination are essential to rule out organic disease. Laboratory testing (CBC, CRP, celiac serology), stool studies, and age-appropriate endoscopy may be warranted to exclude differential diagnoses. Emerging biomarkers, such as fecal calprotectin and mucosal cytokine profiles, show promise for differentiating inflammatory from functional disorders and guiding management, though their routine use remains investigational.

Treatment & Management

Management is tailored to symptom severity, predominant features, and patient preferences. First-line interventions include dietary modification (low FODMAP diet), psychological therapies (cognitive-behavioral therapy, gut-directed hypnotherapy), and pharmacological agents targeting motility (laxatives, antidiarrheals) or neural signaling (antispasmodics, low-dose tricyclic antidepressants). Probiotics and prebiotics may restore microbiome balance and modulate immune responses. Education, reassurance, and a strong therapeutic alliance are critical for optimizing adherence and outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in understanding and therapeutically targeting the neuroimmune axis. Novel agents include 5-HT3 antagonists, bile acid modulators, peripherally acting opioid receptor antagonists, and drugs targeting mast cell stabilization or cytokine signaling. Fecal microbiota transplantation (FMT) and next-generation probiotics are under investigation for refractory cases. Neuromodulation techniques, such as transcutaneous vagal nerve stimulation, offer non-pharmacological alternatives. Precision medicine approaches leveraging multi-omics and individualized immune/microbiome profiling are poised to transform management paradigms.

Guideline Recommendations

Recent consensus guidelines (e.g., American College of Gastroenterology, Rome Foundation) recommend a multi-modal, stepwise approach prioritizing non-pharmacological interventions and patient-centered care. Guidelines emphasize the role of the neuroimmune axis in both diagnosis and management, advocating for dietary, psychological, and microbiome-targeted therapies alongside judicious pharmacotherapy. Biomarker-guided strategies and shared decision-making are encouraged to optimize outcomes.

Conclusion

Enteric neuroimmune axis dysfunction is central to the pathogenesis and clinical manifestations of functional gut disorders. Advances in mechanistic understanding have informed novel diagnostic and therapeutic strategies, with a shift towards precision medicine and multi-modal care. Ongoing research into neuroimmune-microbiome interactions and targeted interventions holds promise for improved outcomes and quality of life in affected patients. Clinicians should remain abreast of evolving evidence and guidelines to deliver optimal, individualized care.